Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway

Liu, Shixiong; Zhou, Yun; Chen, Yarong; Qiao, Yuqin; Bai, Lumucao; Zhang, Shenhua; Men, Dongfang; Zhang, Haibu; Pan, Fen; Gao, Yongshen; Wang, Jijing; Wang, Yuping

doi:10.1016/j.intimp.2024.112828

International Immunopharmacology

2024

DOI: 10.1016/j.intimp.2024.112828

|View full text |Cite

Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway

Shixiong Liu,

Yun Zhou,

Yarong Chen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition

Piva,

Gharari,

Labrador

et al. 2024

Cancers

View full text Add to dashboard Cite

The metabolic reprogramming characteristic of cancer cells, including the Warburg effect, has long been recognized as a hallmark of malignancy. This commentary explores three recent investigations focusing on the role of wild-type IDH2 in cancer and immune cell function. The first publication identifies wild-type IDH2 as a crucial factor in the survival of triple-negative breast cancer (TNBC) cells, with its inhibition leading to disrupted energy metabolism, reduced tumor growth, and enhanced apoptosis. The second analysis examines the role of IDH2 in CD8+ T cells, revealing that its inhibition promotes the differentiation of memory T cells, thereby enhancing the efficacy of cell-based immunotherapies like CAR T cells. A third investigation supports these findings, demonstrating that IDH2 inhibition in CAR T cells reduces exhaustion, enhances memory T cell formation, and improves anti-tumor efficacy. Collectively, these reports highlight wild-type IDH2 as a promising therapeutic target, with potential applications as a two-edged sword in both cancer treatment and immunotherapy. The development of specific wild-type IDH2 inhibitors could offer new avenues for therapy, particularly in tumors reliant on IDH2 activity as well as in enhancing the effectiveness of CAR T cell therapies.

show abstract

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition

Piva,

Gharari,

Labrador

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway

Cited by 1 publication

References 37 publications

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition

Contact Info

Product

Resources

About